Phase I Chinese PK

NCT00503711 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid, Malignant Tumors

Interventions

DRUG: Vandetanib
DRUG: Vandetanib 300 mg

Sponsor

Genzyme, a Sanofi Company